GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has GenSight Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SIGHT is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SIGHT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: SIGHT exceeded the French Biotechs industry which returned 30.6% over the past year.
Return vs Market: SIGHT exceeded the French Market which returned 40.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is GenSight Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StGenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?
1 month ago | Simply Wall StThe GenSight Biologics (EPA:SIGHT) Share Price Has Gained 292%, So Why Not Pay It Some Attention?
3 months ago | Simply Wall StAnalysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long
Is GenSight Biologics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SIGHT (€8.38) is trading below our estimate of fair value (€12.84)
Significantly Below Fair Value: SIGHT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SIGHT is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: SIGHT is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SIGHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SIGHT is overvalued based on its PB Ratio (33x) compared to the FR Biotechs industry average (4.2x).
How is GenSight Biologics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SIGHT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: SIGHT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SIGHT's is expected to become profitable in the next 3 years.
Revenue vs Market: SIGHT's revenue (48.7% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: SIGHT's revenue (48.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SIGHT is forecast to be unprofitable in 3 years.
How has GenSight Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SIGHT is currently unprofitable.
Growing Profit Margin: SIGHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SIGHT is unprofitable, and losses have increased over the past 5 years at a rate of 13.9% per year.
Accelerating Growth: Unable to compare SIGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SIGHT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (18.9%).
Return on Equity
High ROE: SIGHT has a negative Return on Equity (-291.55%), as it is currently unprofitable.
How is GenSight Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: SIGHT's short term assets (€43.8M) exceed its short term liabilities (€17.1M).
Long Term Liabilities: SIGHT's short term assets (€43.8M) exceed its long term liabilities (€18.6M).
Debt to Equity History and Analysis
Debt Level: SIGHT's debt to equity ratio (141.6%) is considered high.
Reducing Debt: SIGHT's debt to equity ratio has increased from 2.1% to 141.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SIGHT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SIGHT has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 13.6% each year.
What is GenSight Biologics's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SIGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SIGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SIGHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SIGHT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SIGHT's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bernard Gilly (63 yo)
Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He is Independent Chairman at EyeTechCare SA. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceutical...
CEO Compensation Analysis
Compensation vs Market: Bernard's total compensation ($USD1.10M) is above average for companies of similar size in the French market ($USD539.15K).
Compensation vs Earnings: Bernard's compensation has increased whilst the company is unprofitable.
Experienced Management: SIGHT's management team is considered experienced (3.6 years average tenure).
Experienced Board: SIGHT's board of directors are considered experienced (9.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54%.
GenSight Biologics S.A.'s company bio, employee growth, exchange listings and data sources
- Name: GenSight Biologics S.A.
- Ticker: SIGHT
- Exchange: ENXTPA
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €422.435m
- Shares outstanding: 50.41m
- Website: https://www.gensight-biologics.com
Number of Employees
- GenSight Biologics S.A.
- 74, rue du Faubourg Saint-Antoine
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and ce...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/12 21:36|
|End of Day Share Price||2021/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.